Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353295 | 1.00 | L3MBTL1 (0.35) | L3MBTL1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL5366821 | 1.00 | L3MBTL1 (0.35) | L3MBTL1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL5355078 | 0.83 | ALDH1A1 (0.43) | L3MBTL1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL5357831 | 0.78 | MEN1 (0.30) | MEN1KMT2APOLB | |
| SCHEMBL5357843 | 0.78 | MEN1 (0.30) | MEN1KMT2APOLB | |
| SCHEMBL5370380 | 0.75 | KMT2A (0.34) | L3MBTL1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL5355911 | 0.75 | KMT2A (0.34) | L3MBTL1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL5355903 | 0.75 | KMT2A (0.34) | L3MBTL1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL5350221 | 0.72 | MAPT (0.50) | L3MBTL1MEN1KMT2AMAPTPOLB | |
| SCHEMBL5354363 | 0.68 | KMT2A (0.34) | ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | L3MBTL1 1685/4885ALDH1A1 1391/4885GAA 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.